The evidence desk
Follow the source.
We use clinician and public-health guidance for medical context, and provider pages for descriptions of their own services. A service claim is not evidence that one provider is clinically better than another.
Checked September 27, 2026. Prices, coverage and availability can change. Research captures are retained in this publication's private repository; personal patient data is not used.
- UK public health guidance
NHS: Postmenopausal bleeding ↗
Source checked 2026-09-27
- Provider product page
CoreAge Rx: estrogen product and care information ↗
Source checked 2026-09-27
- Provider treatment page
Alloy: hormone replacement therapy ↗
Source checked 2026-09-27
- Provider product catalog
Alloy: solutions and product prices ↗
Source checked 2026-09-27
- Provider service information
Evernow: membership and pay-per-visit care ↗
Source checked 2026-09-27
- Provider treatment page
Evernow: hormone therapy ↗
Source checked 2026-09-27
- Provider treatment and billing page
Midi: hormone therapy costs and coverage ↗
Source checked 2026-09-27
- Provider service information
Midi: menopause care ↗
Source checked 2026-09-27
- Professional patient guidance
ACOG: Hormone Therapy for Menopause ↗
Source checked 2026-09-27
- UK public health guidance
NHS: types of hormone replacement therapy ↗
Source checked 2026-09-27
- UK public health guidance
NHS: benefits and risks of HRT ↗
Source checked 2026-09-27
- UK medicine information
NHS: about vaginal oestrogen ↗
Source checked 2026-09-27
- Federal regulatory explanation
FDA: Understanding the Risks of Compounded Drugs ↗
Source checked 2026-09-27
- Federal regulatory announcement
FDA: February 12, 2026 approval of initial hormone-therapy label changes ↗
Source checked 2026-09-27
- Federal patient and labeling explanation
FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms ↗
Source checked 2026-09-27